drugset / Trial / NCT07418749
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
Timeline
- Start
- 2026-03-30
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Pemetrexed | Small molecule | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |
| Comparator | Topotecan | Small molecule | — | — |